Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis

Chennakesavulu, S.; Mishra, Amiya Kanta; Akkiraju, Sudheer; Sowmya, C.; Reddy, C. Suryaprakash; Bhargav, Eranti

doi:10.1016/j.ajps.2017.08.005

Cited by 57 publications

(22 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Produced liposomes were freeze dried with mannitol to acquire dry powder formulation and evaluated using Andersen Cascade Impactor. FPF and MMAD values were 45-50% and <5 µm, respectively [54]. As a result, it is seen that liposomal formulations can be obtained with different aerodynamic properties.…”

Section: Liposomesmentioning

confidence: 85%

Development of dry powder inhaler formulations for drug delivery systems

Akdag¹

2019

Sanat

View full text Add to dashboard Cite

Oral or parenteral administration of drugs to treat lung diseases is met with several challenges, including delivery of the active substance in insufficient amounts, inability to produce the desired effect at the target region, and severe systemic side effects. The best solution to this problem is the pulmonary administration of drugs. Although several formulations for administering inhaled medications such as nebulizers and metered-dose inhalers are available, dry powder inhalers (DPIs) are particularly advantageous owing to their ability to administer a high amount of active ingredient in a short time and higher stability than that of aqueous formulations. Similar to all inhaler formulations, one of the major problems encountered in DPIs is the inability of the active substance to reach the peripheral lungs in sufficient quantity. Moreover, reproducible results are difficult to obtain due to different inhalation capacities among individuals. This review provides the readers with a general perspective on different approaches used in developing various DPIs. Moreover, the review discusses the aerodynamic parameters of these formulations. DPIs developed with novel manufacturing methods are safe with increased therapeutic efficacy, as demonstrated by the results of their in vitro and in vivo safety and efficacy studies. These findings indicate that DPIs could serve as a promising modality for pulmonary drug delivery.

show abstract

Section: Liposomesmentioning

confidence: 85%

Development of dry powder inhaler formulations for drug delivery systems

Akdag¹

2019

Sanat

View full text Add to dashboard Cite

show abstract

“…However, Spd‐AKF‐PLGA NPs can be more efficiently distributed into lung tissue than AKF‐PLGA NPs due to Spd‐mediated intracellular uptake and long blood circulation, resulting in an increase in the intracellular AKF concentration in lung cells. In the histopathological analysis, Spd‐AKF‐PLGA NP treatment significantly reduced neutrophil infiltration (Chennakesavulu et al, ).…”

Section: Neutrophil‐targeted Drug Delivery In Respiratory Diseasesmentioning

confidence: 99%

Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

Chellappan

Yee

Xuan

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Neutrophils are essential effector cells of immune system for clearing the extracellular pathogens during inflammation and immune reactions. Neutrophils play a major role in chronic respiratory diseases. In respiratory diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, lung cancer and others, there occurs extreme infiltration and activation of neutrophils followed by a cascade of events like oxidative stress and dysregulated cellular proteins that eventually result in apoptosis and tissue damage. Dysregulation of neutrophil effector functions including delayed neutropil apoptosis, increased neutrophil extracellular traps in the pathogenesis of asthma, and chronic obstructive pulmonary disease enable neutrophils as a potential therapeutic target. Accounting to their role in pathogenesis, neutrophils present as an excellent therapeutic target for the treatment of chronic respiratory diseases. This review highlights the current status and the emerging trends in novel drug delivery systems such as nanoparticles, liposomes, microspheres, and other newer nanosystems that can target neutrophils and their molecular pathways, in the airways against infections, inflammation, and cancer. These drug delivery systems are promising in providing sustained drug delivery, reduced therapeutic dose, improved patient compliance, and reduced drug toxicity. In addition, the review also discusses emerging strategies and the future perspectives in neutrophil-based therapy. K E Y W O R D S nanoparticle, neutrophils, novel drug delivery, pulmonary, respiratory diseases

show abstract

“…-A variety of lipid combinations for the preparation of liposomes are available, which provide improved physical stability, dispersion, and destruction in the body [46]. -The liposomes also improve the response of antifibrotic drugs by enhancing permeability, decreased side effects, high-vascular density, and retention time at infected sites [39,48]. -Varieties of therapeutic and diagnostic agents are encapsulated in liposomes for targeting the lung disease [39,48].…”

Section: Liposomesmentioning

confidence: 99%

“…-The liposomes also improve the response of antifibrotic drugs by enhancing permeability, decreased side effects, high-vascular density, and retention time at infected sites [39,48]. -Varieties of therapeutic and diagnostic agents are encapsulated in liposomes for targeting the lung disease [39,48]. -Easy modification of surface using biocompatible and inert polymers, which protect the drug from the external environment, reduced opsonization and enhanced circulation time [49,50].…”

Section: Liposomesmentioning

confidence: 99%

Novel Nanoparticulate Systems for Idiopathic Pulmonary Fibrosis: A Review

Dudhat

Patel

2020

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the model of a substantial and heterogeneous gathering of pneumonic issues, mostly constant and dynamic, normally known as interstitial lung disease. In the course of the most recent couple of decades, IPF has been progressively perceived as a noteworthy neglected therapeutic need in respiratory pharmaceutical and has turned into the focal point of exceptional research action. This is because of the ways that IPF frequency is expanding around the world, with rates (and sadly forecast) that are fundamentally the same as those of numerous types of growth. Clinical research on IPF has been gigantically progressing, coming full circle in the current revelation of two sheltered and compelling medications, now at long last made accessible to patients. Ordinary treatment for lung disease is related to the absence of specificity and access to the typical cells bringing about cytotoxicity, lessened cell take-up, tranquilize obstruction, and quick medication freedom from the body. The rise of nanotechnology has reformed the treatment of lung diseases like IPF. The focal point of nanotechnology is to target abnormal alveolar epithelial cells (AECs) with enhanced bioavailability and diminished poisonous quality. Nanoparticulates have the potential for IPF treatment by increasing particular access to the abnormal AECs because of surface modifiability and littler size. This audit article additionally features the attributes, ongoing advances in the planning of NPs, and helpful results.

show abstract

Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis

Cited by 57 publications

References 10 publications

Development of dry powder inhaler formulations for drug delivery systems

Development of dry powder inhaler formulations for drug delivery systems

Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

Novel Nanoparticulate Systems for Idiopathic Pulmonary Fibrosis: A Review

Contact Info

Product

Resources

About